CS 036
Alternative Names: CS-036; IOT-032Latest Information Update: 25 Apr 2025
At a glance
- Originator Inorbit Therapeutics AB
- Developer Cereno Scientific
- Class Cardiovascular therapies; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 25 Apr 2025 Discontinued - Preclinical for Cardiovascular disorders in Sweden (unspecified route)
- 28 Jan 2024 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Sweden
- 06 Mar 2020 CS 036 is available for licensing as of 06 Mar 2020. www.cerenoscientific.com